G
Gate Neurosciences
A healthcare company that offers neuroscience-related medical services
About Gate Neurosciences
Gate Neurosciences is a biotech startup that focuses on developing innovative treatments for central nervous system (CNS) diseases. The company's mission is to provide a new generation of safe, potent, and rapid-acting therapies for the nearly 1 billion people globally who suffer from neuropsychiatric and cognitive disorders.
Gate Neurosciences operates in the biotech and healthcare market, serving patients with CNS disorders, including depression. The company's business model revolves around the development and commercialization of novel therapies that enhance synaptic function, which is the biological basis for many CNS disorders.
The company's primary revenue stream is expected to come from the sale of its therapeutic candidates once they have been approved for use. Their lead program, zelquistinel, is an oral NMDAR PAM (a type of drug that enhances the function of the NMDA receptor in the brain) that has shown promising results in a Phase 2a study for Major Depressive Disorder. The next Phase 2 study is set to be initiated in 2023.
The team at Gate Neurosciences, led by President and CEO Michael G. McCully, has decades of experience in researching CNS disease biology and improving the treatment of CNS disorders. This deep expertise positions the company well for meaningful innovation in the field.
Source: Dealroom company dataAt a glance
- Status
- Acquired
- Founded
- 2019
- Headquarters
- Indianapolis, United States
- Employees
- 1
- Open positions
- None listed
- Dealroom signal
- 58.8/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITION✓Exit | May 2025 | $0 | — | Syndeio Biosciences | — |
| EARLY VC✓Equity / VC | Oct 2022 | $25M | $100M | Thornapple River Capital · BioCrossroads · Innoviva | ↗ |
Growth signals
Latest recorded traffic for Gate Neurosciences is 130 monthly website visits, down 93.8% over the last three months. Gate Neurosciences's team declined 66.7% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
Thornapple River Capital
BioCrossroads
Innoviva
Other known investors1 additional known investor
Syndeio Biosciences
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Gate Neurosciences on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Gate Neurosciences’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.